<DOC>
	<DOCNO>NCT00688246</DOCNO>
	<brief_summary>RATIONALE : Learning effect exemestane bone mineral density postmenopausal woman increase risk breast cancer may help plan treatment , decrease risk break bone , help patient live comfortably . PURPOSE : This research study measure bone mineral density postmenopausal woman increase risk develop breast cancer receive exemestane clinical trial CAN-NCIC-MAP3 .</brief_summary>
	<brief_title>Bone Mineral Density Postmenopausal Women Increased Risk Developing Breast Cancer And Who Are Receiving Exemestane Clinical Trial CAN-NCIC-MAP3</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess percentage change bone mineral density ( BMD ) measure dual x-ray absorptometry ( DEXA ) scan spine ( L1-L4 ) total hip 2 year randomization ( registration MAP.3B protocol ) . Secondary - To assess percentage change BMD measure DEXA scan spine ( L1-L4 ) , total hip 5 year randomization ( registration MAP.3B protocol ) . - To compare proportion woman develop BMD spine ( L1-L4 ) total hip absolute threshold value osteoporosis ( T score ≤ -2.5 SD mean peak bone mass young woman ) treatment group . - To examine pattern change BMD parameter bone biomarkers ( i.e. , PINP NTx ) time impact covariants use exploratory longitudinal analysis . - To compare proportion woman develop clinical skeletal fracture treatment group . OUTLINE : Patients undergo bone mineral density ( BMD ) measurement dual x-ray absorptometry ( DEXA ) . Blood specimen collect baseline 1 year , 5 year stored central laboratory future assay bone biomarkers . If subject withdraws core MAP.3 study 5 year , bone density measurement serum bone biomarkers obtain unless perform within past 3 month . Patients may continue follow MAP.3 core study fracture ( MAP.3 study endpoint ) minimum 5 year randomization .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At increase risk develop breast cancer enrol clinical trial CANNCICMAP3 Bone mineral density ( BMD ) ( measure dual xray absorptometry [ DEXA ] scan within 12 month prior randomization core protocol [ MAP.3 ] ) T score &gt; 2.0 standard deviation ( i.e. , 2.0 standard deviation average peak BMD young adult woman ) spine ( L1L4 ) total hip Serum bone biomarkers ( i.e. , serum Ntelopeptide serum aminoterminal procollagen 1 extension peptide ) must obtain within 8 week prior registration study PATIENT CHARACTERISTICS : Postmenopausal , define one following : Over 50 year age spontaneous menses least 12 month study entry 50 year age menses ( spontaneous secondary hysterectomy ) least 12 month study entry AND folliclestimulating hormone level within postmenopausal range Underwent prior bilateral oophorectomy Available collection serum sample BMD ( DEXA ) scan protocol define time ( i.e. , BMD scan year 2 5 site ) No history fragility fracture ( i.e. , break bone occur fall stand height less amount trauma ) No malabsorption syndrome ( e.g. , untreated celiac disease , clinically relevant vitamin D deficiency , active hyper hypoparathyroidism ) No Paget disease metabolic bone disease ( e.g. , osteomalacia osteogenesis imperfecta ) No Cushing disease pituitary diseases No inflammatory disease ( ) ( e.g. , inflammatory bowel disease , rheumatoid arthritis , lupus , psoriasic arthritis , ankylose spondylitis , autoimmune hepatitis ) PRIOR CONCURRENT THERAPY : More 3 month since prior bone drug , bisphosphonates , teriparatide ( parathyroid hormone [ PTH ] ) , sodium fluoride , calcitonin ( Miacalcin® ) , strontium , highdose vitamin D ( i.e. , vitamin D3 &gt; 2,000 IU/day calcitriol ) No prior bisphosphonate therapy duration 6 month total lifetime No concurrent anabolic chronic oral corticosteroid ( equivalent 5 mg prednisone day high 2 week within past 6 month likely require ongoing therapy ) Concurrent inhale steroid allow No concurrent medication may effect study endpoint study , include follow : Anticonvulsants Sodium fluoride daily dos &gt; 5 mg/day period exceed 1 month Anabolic steroid Teriparatide ( parathyroid hormone ) Bisphosphonates , except woman develop osteoporosis study ; patient may advise start bone medication ( i.e. , strontium , calcitonin , highdose Vitamin D ( i.e. , Vitamin D3 &gt; 2000 IU/day calcitriol ) discretion physician</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>breast cancer</keyword>
</DOC>